OUHSC Research News – Monday, July 18, 2022
Published: Monday, July 18, 2022
OUHSC Research News – Monday, July 18, 2022
Notices and Reminders
SoonerTrack II Go-Live Announcement
The Office of Research Administration (ORA) is pleased to announce that the SoonerTrack II system is now live! This new system has replaced the SoonerTrack I system used to route grant applications and agreements. The launch webpage for the system is https://fs.ou.edu. User guides and training materials are available at https://research.ouhsc.edu/research-administration/soonertrack-ii-support
If you have any questions, please contact soonertrackhelpdesk@ouhsc.edu.
**Please be aware that beginning July 11, all SoonerTrack tickets in Pre-Submission status (tickets that have not yet reached ORA) MUST be resubmitted through the new SoonerTrack.
Important SoonerTrack Update
Please note that to be added to routing forms as Principal Investigator (PI) or personnel, you must log into https://fs.ou.edu as soon as possible. Other than logging in and out, you do not need to do anything else at this time. However, if you do not perform this initial login step, your department support will not be able to route forms for you nor will other researchers be able to add you to their projects in SoonerTrack. If you are routing a proposal/agreement in SoonerTrack II and can’t find your department, please contact your business administrator. If you have any questions, please contact us at soonertrackhelpdesk@ouhsc.edu.
SoonerTrack II Training Opportunities
Pre-scheduled SoonerTrack II training sessions are available at the following dates and times. All sessions are the same, so register for the one that best fits your schedule. Additional dates will be provided as needed (These sessions will be conducted via Zoom).
- Wednesday, July 20, 2022, 1:30 PM - 2:30 PM - Register here
- Thursday, July 28, 2022, 10:00 AM – 11:00 AM- Register here
The Office of Vice President for Research (OVPR) and the Office of Research Administration (ORA) at the OU Health Sciences Center Announcing the Launch of the Newly Redesigned Website
We are excited to announce the launch of our newly redesigned website. The new design allows for streamlined menus and clear navigation, and offers quick and easy access to essential information for our faculty and staff. Explore the website at https://research.ouhsc.edu. We welcome your feedback. Please send any questions or comments to oradmin@ouhsc.edu.
NIH Reminder: All NIH-funded clinical trials are expected to register and submit results information to Clinicaltrials.gov, as per the “NIH Policy on Dissemination of NIH-Funded Clinical Trial Information for competing applications and contract proposals. The requirements for registration and results reporting are:
- Recipients must ensure that their NIH-funded clinical trials are registered at ClinicalTrials.gov for public posting no later than 21 days after enrollment of the 1st participant.
- Results information must be submitted to ClinicalTrials.gov no later than one year after primary completion date (with limited exceptions).
If your RPPR has associated clinical trials that do not comply with these requirements, you may receive errors that prevent the RPPR from being submitted.
Workshops and Seminars
Webinar I: Understanding the New NIH Data Management and Sharing Policy
Date: Thursday, August 11, 1/24/22, 12:30 - 2:30 PM (Central)
Description: The NIH Office of Science Policy (OSP) and the Office of Extramural Research (OER) invite you to join them for an engaging and interactive webinar focused on the new DMS policy which goes into effect on January 25, 2023. In this webinar, you will learn about DMS policy expectations, the applicability of the policy, how to prepare a Data Management and Sharing Plan, and considerations for sharing data responsibly. Don't miss this valuable opportunity to hear from policy experts and get your questions answered. Registration: https://vfairs.zoom.us/webinar/register/WN_CtZuYKxtTeioXptg43JDgg
Webinar II: Diving Deeper into the New NIH Data Management and Sharing Policy
Date: Thursday, September 22, 2022 / 12:30 - 2:30 PM (Central)
Description: The NIH Office of Science Policy (OSP) and the Office of Extramural Research (OER) invite you to join them for an engaging and interactive webinar focused on the new DMS policy which goes into effect on January 25, 2023. In this second webinar of the series, we will expand upon the information presented in the first webinar and dive deeper into topics including privacy protections for data from human participants and justifiable limitations on sharing data. Don't miss this valuable opportunity to hear policy experts provide the latest information and to get your questions answered.
Registration: https://vfairs.zoom.us/webinar/register/WN_3y9GFMc2SsWpv2GhIzOGsg
Data Science Workshop: Edit live Jupyter notebooks from the comfort of your favorite text editor
Speaker: Blaine Mooers, PhD
Date: Thursday, July 21, noon to 1 PM, virtual
Abstract: Jupyter notebooks are computational notebooks that support interactive computing in web browsers. These notebooks are popular with Python programmers. However, you can use the notebooks with over 100 other programming languages, including R, Julia, and C. The notebooks support the interleaving between blocks of code text written in markdown, math equations rendered with MathJax, and embedded images. Jupyter notebooks hold the promise of supporting literate programming and thereby reproducible research. Some workers have assembled research papers and even books from Jupyter notebooks. However, the Jupyter platform lacks several essential features of modern text editors. I will present two software solutions developed by others that address parts of this problem: GhostText (https://ghosttext.fregante.com/) and Quarto (https://quarto.org/).
GhostText is a browser extension that supports sending the text in any browser textarea (those boxes in webpages where you can enter free-form text) to your favorite text editor (e.g., Vim, NeoVim, VSC, Emacs, Sublime Text, Atom). The live cell of a Jupyter or Colab notebook is also a textarea. You can insert your favorite snippets with your text editor, and the textarea updates instantly. I also use GhostText to edit LaTeX documents in Overleaf, the browser-based LaTeX editor. I use the latter to prepare research papers, grant applications, slideshows, and posters.
Quarto is a command line tool that supports scientific publishing. Quarto uses Jupyter and Pandoc to convert Jupyter Notebooks and other documents into HTML, PDF, and docx files. Quarto works with Jupyter Lab, Rstudio, Visual Studio Code, Vim, Emacs, and Sublime Text. Quarto streamlines what had been a convoluted process.
Zoom Link: https://zoom.us/j/93134764583?pwd=emNmS2ZndFQrUnR2STRhdDRSc2EvUT09
OUHSC Funding Opportunities
Presbyterian Health Foundation (PHF) Bridge Grant Program – Request For Applications
- Cycle II PHF Bridge Grant Program Deadline: July 29, 2022
The primary objective of the PHF Bridge Grant Program is to provide funding to enhance OUHSC faculty competitiveness for extramural funding. OUHSC Principal Investigators are eligible if they meet the following criteria: 1) have submitted an extramural application within the past 18 months that was scored but not funded, 2) are requesting over $750,000 in total direct costs and over $200,000 in total facilities and administration (F&A) costs; and 3) received a review that ranks applications and provides critiques.
IMPORTANT UPDATE: This program can now provide funding for up to $100,000 for one year. SALARY and FRINGE BENEFITS may be requested for the Principal Investigator(s) up to $25,000 in total (salary + fringe benefits = $25,000) with the remaining portion, $75,000, used to support the project costs. Guidelines and Application Form are attached or can be found here. If you have any questions, please email VPR@ouhsc.edu
The Presbyterian Health Foundation and the Oklahoma Center for Therapeutic Sciences 2022 pilot award
The Presbyterian Health Foundation (PHF) and the Oklahoma Center for Therapeutic Sciences (CTS) are soliciting proposals for Investigator Seed Grant Awards in drug and probe discovery. The current RFA is focused on funding pilot projects that utilize the Drug and Target Discovery (DTD) High Throughput Screening (HTS) Facility and the Laboratory of Molecular Structure and Function (MSF). DTD can perform screens of its 7 chemical libraries (~100,000 compounds) using cell-based high-content imaging, as well as fluorescence, fluorescence polarization, TR-FRET, absorbance, and luminescence of cell-based assays or assays using purified components. DTD has cell culture facilities and a full suite of detection, robotic, and imaging equipment designed to facilitate work in microwell plates (96-or 384-well formats). The Facility will assist investigators in the design and development of screen assays that can use all currently available assay readouts and formats. Funding for pilot projects that utilize MSF will be focused on the use of its structure-guided software tools.
Documents for the pilot award announcement and a brochure describing the capabilities of CTS are attached.
If you have any questions, please contact Matthew Hart, Ph.D. at Matthew-J-Hart@ouhsc.edu
Office of Technology Commercialization presents the following opportunities for researchers to engage with industry (click here for more information, or email otc@ou.edu or gina-mcmillen@ouhsc.edu).
- Almirall, a global biopharmaceutical company focused on skin health, is seeking partnering opportunities is medical dermatology. Of interest are target immune-inalfmmatory pathways with rationale for dermatological indications, non-melanoma skin cancer or rare dermatological indications. Any therapeutic modality and all stages of development will be considered. Out of scope: drug delivery reformulations, natural products, aesthetic and cosmetic products. Submission entails a 1-pg non-confidential summary of technology with optional supplemental information. (deadline 08/05).
- Mars Petcare is seeking fermentation technologies to transform raw materials and boost product flavor and attractiveness for cats and dogs. Plant-based raw materials/substances and technologies with opportunity to up-cycle agricultural side stream and human food industry by products are of high interest. Novel fermentation equipment/systems and bio-separation or purification technologies are also of interest provided they allow for fermentation or improve over existing processes. Submission entails a 1-pg non-confidential summary of technology with optional supplemental information. (deadline 08/12).
- The sustainable materials division of Faurecia, a tier-one automotive supplier interested in developing low carbon footprint alternative skins/leather/textiles, is seeking sustainable leather substitutes to decrease emission factors of interior parts. All kinds of subsitutes or feedstock are of interest. Submission entails a 1-pg non-confidential summary of technology with optional supplemental information. (deadline 08/12).
NIH Notices
NOTE: When only one application is allowed per Institution according to the sponsor instructions, a one-page letter of intent summarizing the proposed project should be submitted to the Vice President for Research at least two months prior to the application deadline (unless otherwise noted). The letters of intent will be reviewed and a single application will be chosen for submission from the University.
NIH Funding Opportunities
- Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required)
(PAR-22-189)
Application Receipt Date(s): September 11, 2025
- Modern Equipment for Shared-use Biomedical Research Facilities: Advancing Research-Related Operations (R24 Clinical Trials Not Allowed)
(PAR-22-190)
Application Receipt Date(s): November 07, 2022
- Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
(PAR-22-192)
Application Receipt Date(s): September 11, 2025
- Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required)
(PAR-22-193)
Application Receipt Date(s): September 11, 2025
- Point-of-Care Technologies Research Network: Technology Research and Development Centers (TRDC) (U54 Clinical Trial Optional)
(PAR-22-203)
Application Receipt Date(s): January 07, 2023
- Research to Action: Assessing and Addressing Community Exposures to Environmental Contaminants (R01 Clinical Trial Optional)
(PAR-22-210)
Application Receipt Date(s): Multiple dates, see announcement.
- NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
(PAR-22-216)
Application Receipt Date(s): July 01, 2025
- HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K01 - Clinical Trial Required)
(PAS-22-206)
Application Receipt Date(s): November 12, 2025
- HEAL Initiative: Career Development Awards in Implementation Science for Substance Use Prevention and Treatment (K23 - Clinical Trial Required)
(PAS-22-207)
Application Receipt Date(s): November 12, 2025
- More Monitoring of Cognitive Change, Continued (M3C3) (U2C Clinical Trial Optional)
(RFA-AG-23-021)
Application Receipt Date(s): October 20, 2022
- HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3, Clinical Trials Optional)
(RFA-AT-23-001)
Application Receipt Date(s): November 21, 2022
- HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required)
(RFA-AT-23-002)
Application Receipt Date(s): November 21, 2022
- Limited Competition: Cancer Immune Monitoring and Analysis Centers (CIMACs) and Cancer Immunologic Data Center (CIDC) (U24 Clinical Trial Not Allowed)
(RFA-CA-22-038)
Application Receipt Date(s): Not Applicable
- HEAL Initiative: Multilevel Interventions to Reduce Harm and Improve Quality of Life for Patients on Long Term Opioid Therapy (MIRHIQL) (R01 Clinical Trial Required)
(RFA-DA-23-041)
Application Receipt Date(s): September 27, 2022
- HEAL Initiative: Multilevel Interventions to Reduce Harm and Improve Quality of Life for Patients on Long Term Opioid Therapy (MIRHIQL): Resource Center (U24- Clinical Trial Optional)
(RFA-DA-23-042)
Application Receipt Date(s): September 27, 2022
- HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants (R01 - Clinical Trials Optional)
(RFA-DA-23-051)
Application Receipt Date(s): February 02, 2023
- Mass Spectrometric Assays for the Reliable and Reproducible Detection of Proteins/Peptides of Importance in Type 1 Diabetes (T1D) Research (U01 Clinical Trial Not Allowed)
(RFA-DK-21-031)
Application Receipt Date(s): October 26, 2022
- Human Islet Research Network - Consortium on Targeting and Regeneration (HIRN-CTAR) (U01 Clinical Trial Not Allowed)
(RFA-DK-22-009)
Application Receipt Date(s): October 26, 2022
- Chronic Kidney Disease in Children Central Biochemistry Laboratory (U24 Clinical Trial Not Allowed)
(RFA-DK-22-010)
Application Receipt Date(s): October 26, 2022
- Understanding the Pathophysiology and Clinical Course of New-Onset Diabetes Following COVID-19 (U01 Clinical Trial Not Allowed)
(RFA-DK-22-016)
Application Receipt Date(s): December 20, 2022
- Collaborative Research Using Biosamples from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)
(RFA-DK-22-021)
Application Receipt Date(s): October 26, 2023
- Limited Competition for Continuation of the Prospective Study of Chronic Kidney Disease in Children Clinical Coordinating Centers (U01 Clinical Trial Not Allowed)
(RFA-DK-22-504)
Application Receipt Date(s): Not Applicable
- Limited Competition for Continuation of the Prospective Study of Chronic Kidney Disease in Children Data Coordinating Center (U24 Clinical Trial Not Allowed)
(RFA-DK-22-505)
Application Receipt Date(s): Not Applicable
- BRAIN Initiative: Transformative Brain Non-invasive Imaging Technology Development (UG3/UH3 Clinical Trial Not Allowed)
(RFA-EB-22-001)
Application Receipt Date(s): Multiple dates, see announcement.
- Epigenetic Mechanisms Regulating HIV CNS Latency and Neuropathogenesis Using Novel Single Cell Technologies (R01 Clinical Trial Not Allowed)
(RFA-MH-22-280)
Application Receipt Date(s): December 05, 2022
- Epigenetic Mechanisms Regulating HIV CNS Latency and Neuropathogenesis Using Novel Single Cell Technologies (R21 Clinical Trial Not Allowed)
(RFA-MH-22-281)
Application Receipt Date(s): December 05, 2022
- Galvanizing Health Equity Through Novel and Diverse Educational Resources (GENDER) Research Education R25 (R25 Clinical Trial Not Allowed)
(RFA-OD-22-015)
Application Receipt Date(s): January 07, 2023
- Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Diseases (U44 Clinical Trial Required)
(RFA-TR-22-029)
Application Receipt Date(s): July 12, 2023
Other Funding Opportunities
The Melanoma Research Alliance (MRA) - Patient-Centric Clinical Trial Team Science Awards
Description: The Melanoma Research Alliance (MRA) is pleased to announce a Special Opportunity RFP for Team Science Awards focused on patient-centric clinical trials, jointly funded by The Rising Tide Foundation for Clinical Cancer Research (RTFCCR) and MRA. MRA and RTFCCR will jointly support two team awards (each up to $1.5 million) for clinical trials with the potential to provide significant impact to melanoma patients. These awards seek to support novel, interventional clinical trials with the goal of making a significant difference to melanoma patients in the short term. Patient engagement must be actively demonstrated throughout the full life cycle of the clinical trial, including planning and dissemination.
Informational webinars: Informational webinars will be offered on July 26 at 9 am ET & July 28 at 11 AM ET. Applicants are highly encouraged to attend
Letters of Intent Due: October 5, 2022
Invited Full Proposals Due: January 18, 2023
Link to Full Announcement: CureMelanoma.org/RFP
Susan G. Komen Career Catalyst Research (CCR) Grants - call for research proposals from early career investigators
Description: For more than a decade Susan G. Komen Career Catalyst Research (CCR) Grants have fostered promising breast cancer researchers who are in the early stages of their faculty careers, conducting research that has unlocked new knowledge about breast cancer and helped advance patient care. Through this grant mechanism, we seek to support those who will emerge as the next generation of key leaders in the quest to end breast cancer. Eligibility: Junior faculty members working at academic institutions in the United States who have not held any faculty appointment for more than a total of six years are invited to apply for our Career Catalyst Research Grants.
Letters of Intent Deadline: Extended to August 1, 2022
Full Application Due: October 5, 2022
Link to Full Announcement: https://bit.ly/3xmfvcn
Oklahoma Center for Adult Stem Cell Research (OCASCR)
Description: The overall goal of OCASCR is to help adult stem cell and regenerative medicine research thrive in Oklahoma and to serve as a trusted resource for public information on these topics. Grants are accepted for research, equipment, and travel/education, and other areas.